SARMs (Ostarine, LGD-4033, RAD-140, etc.)Banned Substance

• SARMs are not approved by the FDA for any use, and cannot be legally marketed in the US as either a dietary supplement or a drug [1].
  
  That is the entire legal position in one line: there is no approved SARM. ^[1]

• In its warning letters, FDA classifies products marketed as SARMs as unapproved new drugs under the Federal Food, Drug and Cosmetic Act [2].
  
  The reasoning: their labeling and marketing — muscle hypertrophy, strength gains, tissue repair — show intent to affect the structure or function of the body, with no approved application in effect [2].
  
  A "research use only" disclaimer does not change that classification [2]. ^[2]

• Several SARMs, ostarine among them, were developed by pharmaceutical sponsors and taken into human clinical trials before resurfacing as bodybuilding "research chemicals" [18].
  
  FDA guidance says an article authorized for investigation as a new drug, whose substantial clinical investigations have been made public, is excluded from the definition of a dietary supplement [18].
  
  The only escape hatch is prior marketing as a supplement before that investigational application existed [18]. ^[18]

• The supplement industry does not argue with this. The Council for Responsible Nutrition states plainly that SARMs are not legitimate dietary supplements — they are unapproved drugs [4]. ^[4]

• There is a structural reason SARMs were never simply scheduled as steroids. Most of them, ostarine, LGD-4033 and RAD-140 included, are non-steroidal in chemical structure [14]. ^[14]

• The 2014 Designer Anabolic Steroid Control Act widened the Controlled Substances Act's definition of anabolic steroid mainly to capture steroid-structured designer compounds [9].
  
  That is why FDA's SARM enforcement runs through unapproved-new-drug provisions, warning letters and criminal referrals rather than through drug scheduling [2]. ^[9]

• A 2019 Senate bill, the SARMs Control Act, was introduced specifically to close that gap by amending the Controlled Substances Act to cover SARMs directly [8].
  
  It stalled in committee and was never enacted [8]. ^[8]

• In sport the position is older and much simpler. The World Anti-Doping Agency has prohibited SARMs at all times since 2008, listing them under category S1.2, Other Anabolic Agents [6]. ^[6]

• FDA's stated safety rationale is blunt. Life-threatening reactions, liver toxicity among them, have occurred in people using SARM-containing products, and the agency cites potential for increased risk of heart attack and stroke [2]. ^[2]

• Liver injury is the best-documented hazard. Multiple published case reports describe drug-induced liver injury, in both hepatocellular and cholestatic patterns, attributed to LGD-4033, ostarine and RAD-140 [10].
  
  Reported features include jaundice, fatigue, abdominal pain, nausea, and elevated ALT, AST, bilirubin and alkaline phosphatase [11].
  
  Some cases progressed to hepatic encephalopathy or acute liver failure [12]. ^[10]

• One case describes a previously healthy man in his early 40s who developed significant cholestatic liver injury after using ostarine for muscle gain [19].
  
  The injury was confirmed on biopsy [19]. ^[19]

• FDA's documented adverse effects run wider than the liver: heart attack or stroke risk, psychosis and hallucinations, sleep disturbance, sexual dysfunction, and acute liver failure [1].
  
  Also on that list: infertility, pregnancy miscarriage and testicular shrinkage [1]. ^[1]

• A 27-year-old weightlifter with no symptoms at all had routine bloodwork showing an LDL/HDL cardiac-risk ratio of 9.9 after using LGD-4033 and S-23 [13].
  
  The same bloodwork showed hepatocellular enzyme elevation and suppression of the pituitary-gonadal axis [13].
  
  Every value normalized within weeks to two months after he stopped [13]. ^[13]

• Oral SARMs significantly suppress HDL cholesterol, probably by raising hepatic triglyceride lipase [16].
  
  A controlled trial found this did not significantly impair HDL particle cholesterol-efflux function, and whether the suppression meaningfully raises cardiovascular event risk stays unresolved [16]. ^[16]

• The sources disagree about cardiovascular risk, and we are not settling it for you. FDA and Poison Control state SARMs carry an increased risk of heart attack or stroke [1].
  
  A reference-tier evidence review calls cardiovascular event risk unknown, and notes SARMs affect blood lipids less than testosterone replacement does [14].
  
  That is a real gap between public-health warning framing and a more cautious academic read of the same evidence. ^[14]

• Case reports have linked RAD-140 (testolone) to acute myocarditis [17].
  
  The mechanism is unclear, and this stays a single-case-level signal rather than a measured rate [17]. ^[17]

• SARMs suppress the hypothalamic-pituitary-gonadal axis, lowering LH, FSH and testosterone [13].
  
  Clinical trials documented that after as little as 2 weeks of use, though generally less severely than with anabolic steroids [14]. ^[13]

• Poison Control's short-term list: raised blood pressure and heart rate, chest pain, mood swings, psychosis, irritability, anxiety, sleep disturbance, acne and hair loss [5].
  
  Its long-term list: permanent liver damage, testicular atrophy, infertility and gynecomastia in men, plus infertility and miscarriage risk in women [5].
  
  It also notes SARMs can be physically and psychologically addictive, with withdrawal symptoms on stopping [5]. ^[5]

• A systematic review of self-reported SARM users found 54.5% reported some adverse effect [21].
  
  The most common were mood swings (22.4%), decreased testicular size (20.7%) and acne [21]. ^[21]

• Increased tendon-rupture risk turns up in both Poison Control's guidance and a sports-medicine systematic review cited by Cleveland Clinic [5][20]. ^[5]

• 2008 — The World Anti-Doping Agency prohibits SARMs at all times in sport [6].
  
  That status still stands on the current Prohibited List, under category S1.2, Other Anabolic Agents [6]. ^[6]

• 2014 — The Designer Anabolic Steroid Control Act is signed, widening the Controlled Substances Act's definition of anabolic steroid to sweep in steroid-structured designer compounds [9].
  
  It does not squarely capture the many SARMs built on non-steroidal structures [14]. ^[9]

• 2017 — FDA issues a public safety alert against ingesting bodybuilding products containing SARMs [23].
  
  The alert cites life-threatening reactions including liver toxicity, plus increased risk of heart attack and stroke [23]. ^[23]

• 2018 — The Council for Responsible Nutrition, a supplement-industry trade group, issues a voluntary guideline telling its members not to distribute or market SARM-containing products as supplements [4]. ^[4]

• November 2019 — Senators Grassley and Whitehouse introduce the SARMs Control Act (S.2895), which would amend the Controlled Substances Act to regulate SARMs directly [8].
  
  It is referred to the Senate Judiciary Committee, draws no further recorded action, and never becomes law [8]. ^[8]

• April 2023 — FDA issues a consumer update warning that adverse-event reports tied to SARMs keep arriving [1].
  
  It singles out promotion to teens and young adults by social-media influencers [1]. ^[1]

• Mid-2020s onward — FDA keeps issuing warning letters to individual sellers and pursuing criminal actions against distributors, case by case [2].
  
  One example: a warning letter to Titan Sarms LLC dated December 12, 2025, covering LGD-4033, RAD-140, S-4 and YK-11 products [2]. ^[2]

• Where it stands — FDA's current consumer guidance says SARMs still cannot be legally marketed in the US as a dietary supplement or drug [1].
  
  There has never been one comprehensive federal ban. Enforcement remains a rolling, product-by-product process under existing unapproved-new-drug authority [1]. ^[1]

There is no established acute lethal or toxic overdose threshold for SARMs in humans. Poison Control states there is little information on large single acute overdoses [5].

What is documented is sustained high-dose use: people taking SARMs for bodybuilding commonly use roughly 10 times the doses studied in clinical trials [5].

For scale, LGD-4033 has been tested in trials at single doses from 0.1 mg up to 22 mg, and at repeated doses of 0.1–2 mg/day for 3 to 12 weeks [15].

No serious adverse events were reported even at that highest single dose. Non-medical users are commonly reported taking around 5–10 mg/day or more, at unknown risk [15].

Ostarine has been studied clinically at up to 3 mg/day over 12 weeks, for muscle-wasting indications [19].

Documented harm sits well below anything resembling an overdose. A 17-year-old developed biopsy-confirmed drug-induced hepatitis after about one month of daily use of a SARM-containing product, other causes ruled out [5].

The label number may also be fiction. Independent laboratory testing of SARM products bought from retail websites confirmed the labeled SARM present in only about 70% of samples [3].

A different, undeclared SARM appeared in 23%, one sample contained no SARM at all, and measured content ran from 30% to 90% of the label claim [3].

Undeclared pharmaceuticals — tamoxifen, clomifene, testosterone, methandienone, tadalafil — showed up in 30% of samples, and over 60% held more than one active substance [3].

A buyer generally cannot know the actual dose from the label. ^[5]

US Poison Control runs a free online triage tool and the line 1-800-222-1222, staffed 24 hours a day [5].

Use either for a large swallowed dose, for sustained high-dose use, or for any open question about exposure [5].

Where SARMs are kept in a home, Poison Control's storage advice is the ordinary one for medicines: up, away, and out of reach of children [5].

There is no specific antidote for SARM toxicity. Documented clinical management is supportive [5].

In one published pediatric case, a 17-year-old reached an emergency department after two weeks of fatigue, headache, nausea and abdominal pain, with jaundice [5].

Lab work showed hepatitis, other causes were excluded, and serum hepatitis markers peaked on hospital day 4 [5].

Symptoms and labs improved with supportive care and monitoring, and discharge came on hospital day 8 [5].

Other published liver-injury cases follow the same shape: alternative causes excluded, serial liver-function monitoring, supportive care [10].

Most patients improved over weeks to months after stopping, though reported severity ranges from mild transaminase elevation to cholestasis and, in the worst cases, acute liver failure [11].

Poison Control notes overall adverse-effect risk looks similar for teenagers and adults [5].

Teenagers' endocrine systems are still developing, though, so hormonal disruption is an added concern — and teens are exactly who SARM marketing on social media targets [1]. ^[5]